First human test for new schizophrenia shot

NCT ID NCT07484204

Summary

This early-stage study aims to understand how a new long-acting injectable medication for schizophrenia moves through the body and how safe it is. It will involve 48 adults with stable schizophrenia who will receive a single injection. The main goal is to measure drug levels in the blood and track any side effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ratandeep Multispeciality Hospital

    Nagar, India

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.